Sonnet BioTherapeutics Holdings, Inc. (SONN)
| Market Cap | 35.81M |
| Revenue (ttm) | 5.68M |
| Net Income (ttm) | -68.47M |
| Shares Out | 17.22M |
| EPS (ttm) | -10.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $2.01 |
| Previous Close | $2.03 |
| Change ($) | -0.02 |
| Change (%) | -0.99% |
| Day's Open | 2.04 |
| Day's Range | 1.99 - 2.09 |
| Day's Volume | 441,735 |
| 52-Week Range | 1.81 - 7.89 |
PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, ...
PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, ...
Wall Street recommends buying shares of Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) and Sigma Labs Inc. (NASDAQ:SGLB), which you would not expect after these 2 stocks performed so poorly over the...
PRINCETON, NJ / ACCESSWIRE / December 17, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drug...
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s o...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) were down 11% on Wednesday after skyrocketing 56.9% on Tuesday on COVID-19-related news.
About SONN
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced periphera... [Read more...]
| Industry Biotechnology | |
| CEO Michael Pruitt | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol SONN |